Aprepitant, Granisetron, and Dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose Melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial

Ähnliche Einträge

• The NK1 receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma
  von: Egerer, Gerlinde, et al.
  Veröffentlicht: (2010)
• Intravenous amisulpride for the prevention of postoperative nausea and vomiting: two concurrent, randomized, double-blind, placebo-controlled trials
  von: Gan, Tong-Joo, et al.
  Veröffentlicht: (2017)
• The prevention and treatment of nausea and vomiting during tumor therapy
  von: Jahn, Franziska, et al.
  Veröffentlicht: (2022)
• Efficacy of a single preoperative dexamethasone dose to prevent nausea and vomiting after thyroidectomy (the tPONV study): a randomized, double-blind, placebo-controlled clinical trial
  von: Tarantino, Ignazio, et al.
  Veröffentlicht: (2015)
• Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial
  von: Herrstedt, Jørn, et al.
  Veröffentlicht: (2019)